TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Key takeaways from ACC.25: Advances in cardiovascular science
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS
Two separate studies at ACC.25 explored data from the EARLY TAVR trial. One analysis included stroke findings that surprised researchers.
Dapagliflozin improves outcomes for elderly TAVR patients with heart failure
The positive data were presented as part of a late-breaking clinical trial at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.
Cardiologists make case against routine interventions for asymptomatic severe AS
Aortic valve replacement is likely inevitable for patients with asymptomatic severe aortic stenosis. Immediately performing TAVR or SAVR, however, may not always be the answer.
So far, so good: TAVR comparable to open heart surgery after 5 years in low-risk patients
Michael J. Reardon, MD, shared the highly anticipated data with a large audience at ACC.25 in Chicago. Overall, he said, these five-year findings suggest TAVR with a supra-annular, self-expanding valve is a safe and effective alternative to SAVR.

Patients can safely undergo noncardiac surgeries after TAVR without a long delay

However, the study’s authors did find associations between suboptimal TAVR procedures and adverse outcomes.

VIDEO: The state of TAVR in 2022

Michael Mack, MD, a key pioneer in transcatheter aortic valve replacement (TAVR), explains the history of TAVR and where things are headed.

A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare

AFib patients more likely to be hospitalized for heart failure or bleeding following TAVR

The study, published in the American Journal of Cardiology, included data from more than 900 TAVR patients. Overall morality was 22.7% among patients with AFib and 14.4% among patients without AFib.

Tracking TAVR’s impact on gastrointestinal bleeding symptoms

TAVR patients with gastrointestinal bleeding (GIB) were linked to longer lengths of stay and a higher risk of acute kidney injury than patients without GIB.

The Boston Scientific Acurate neo2,. Abbott Portico and the new Edwards Sapien X4 TAVR valves were hot topics of discussion at TCT 2022. #TVT #TVT22 #TVT2022

VIDEO: TAVR's long-term impact on patient care

One thing was clear at TVT 2022 in Chicago: TAVR's popularity over surgery is changing the way physicians think about patient care.

Links to all the late-breaking structural heart studies at TVT 2022

Here are links to more information for all the late-breaking presentations at the 2022 Transcatheter Valve Therapies (TVT) Structural Heart Summit.

A TAVR procedure being performed at Northwestern Medicine in Chicago. These structural heart procedures require a team approach.

VIDEO: How to build a structural heart program

Charles Davidson, MD, clinical chief of cardiology and medical director of the Bluhm Cardiovascular Institute, Northwestern University, explains what hospitals need to consider when starting a new structural heart program.

Resheathing heart valves during TAVR does not increase risk of complications

Researchers tracked both short- and long-term outcomes, sharing their findings in the Journal of the American Heart Association.

Around the web

Radiology Business

The impact of Trump tariffs on iodine contrast media costs

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Radiology Business

Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

TAVR

Key takeaways from ACC.25: Advances in cardiovascular science

New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS

Dapagliflozin improves outcomes for elderly TAVR patients with heart failure

Cardiologists make case against routine interventions for asymptomatic severe AS

So far, so good: TAVR comparable to open heart surgery after 5 years in low-risk patients

Around the web